Hologic (HOLX) is one of the stocks most watched by Zacks.com visitors lately. So, it might be a good idea to review some of ...

Hologic shares remained relatively unmoved today on first-quarter results that fell shy of the Wall Street forecast.

Medical technology company Hologic (NASDAQ:HOLX) in Q4 CY2025 as sales rose 2.5% year on year to $1.05 billion. Its non-GAAP ...

Hologic slips after a Q1 EPS and revenue miss, as gross margin fell 150 bps with Diagnostics weakness offset by strong GYN ...

HOLX's GYN Surgical unit, boosted by MyoSure, Fluent and Gynesonics, drives 10.2% revenue growth and is likely to lift ...

Hologic, a Marlborough-based medical device manufacturer, is expanding its product catalog through the planned $310-million acquisition of Endomagnetics, a breast cancer surgery technology developer.

MARLBOROUGH - Hologic, Inc. (NASDAQ:HOLX) reported fiscal first quarter earnings that fell short of analyst expectations, with revenue of $1.05 billion missing the consensus estimate of $1.07 billion.

The market awaits Hologic's announcement, with hopes high for news of surpassing estimates and providing upbeat guidance for the next quarter. It's important for new investors to ...

Have you looked into how Hologic (HOLX) performed internationally during the quarter ending December 2025? Considering the widespread global presence of this medical device maker, examining the trends ...

MARLBOROUGH, Mass.--(BUSINESS WIRE)--Hologic, Inc. (Nasdaq: HOLX), a global leader in women’s health, today launched Project Health Equality (PHE), a unique initiative that strives to address the ...

Though the vast majority of women are aware of the importance of early screening for various cancers and other life-threatening health conditions, a new survey estimates that nearly half of those in ...